REPORTS

 

Rhetoric and Reality—The Obamacare Evaluation Project: Cost
by Paul Howard, Yevgeniy Feyman, March 2013

Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials
by Avik Roy, April 2012

Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research
by Tomas J. Philipson, Eric Sun, June 2011

Building a Market-Based Health-Insurance Exchange in New York
by Paul Howard, April 2011

Easy Access, Quality Care: The Role for Retail Health Clinics in New York
by Paul Howard, February 2011

How Conflict-of-Interest Rules Endanger Medical Progress and Cures
by Richard A. Epstein, October 2010

Cost of Caution: The Impact on Patients of Delayed Drug Approvals
by Tomas J. Philipson, Eric Sun, June 2010

Time Release: The Effect of Patent Expiration on U.S. Drug Prices, Marketing, and Utilization by the Public
by Dr. Frank R. Lichtenberg, October 2009

Healthier Choice: An Examination of Market-Based Reforms for New York’s Uninsured
by Tarren Bragdon, Stephen T. Parente, September 2009

Forging a New Plan For Health Care: Principles and Priorities for Sustainable Reform
by Douglas Holtz-Eakin, May 15, 2009

In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation
by James R. Copland, Paul Howard, March 2009

HSA Health-Insurance Plans After Four Years: What Have We Learned?
by Dr. Benjamin Zycher, February 2009

Alive and Working: How Access to New Drugs has Slowed the Growth in America's Disability Rates
by Dr. Frank R. Lichtenberg, October 2008

The Truth About Drug Innovation: Thirty-Five Summary Case Histories on Private Sector Contributions to Pharmaceutical Science
by Dr. Benjamin Zycher, Joseph A. DiMasi, Christopher-Paul Milne, June 2008

Comparing Public and Private Health Insurance: Would a Single-Payer System Save Enough to Cover the Uninsured?
by Dr. Benjamin Zycher, October 2007

Why Has Longevity Increased More in Some States than in Others? The Role of Medical Innovation and Other Factors
by Dr. Frank R. Lichtenberg, July 2007

The Human Cost of Federal Price Negotiations: The Medicare Prescription Drug Benefit and Pharmaceutical Innovation
by Dr. Benjamin Zycher, October 2006

Prescription for Progress: The Critical Path To Drug Development
by Robert M. Goldberg, June 2006

Older Drugs, Shorter Lives? An Examination of the Health Effects of the Veterans Health Administration Formulary
by Dr. Frank R. Lichtenberg, October 2005

Are Drug Price Controls Good for Your Health?
by John A. Vernon, Rexford E. Santerre, Carmelo Giaccotto, December 2004


keep in touch     Follow Us on Twitter  Facebook  Facebook


For more information or to speak with one of the experts, contact:

Laura Eyi
Press Officer,
Communications
212-599-7000
leyi@manhattan-institute.org